State of the art treatment for gastric cancer: Future directions

European Journal of Cancer, Supplement

Volumn 2, Issue 7, 2004, Pages 40-47

  Cervantes, A ^a   Georgoulias, V ^b   Falcone, A ^c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF CRETE   (Greece)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Adjuvant; Advanced gastric cancer; Irinotecan; Palliative; Taxanes

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTARABINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ALOPECIA; ANEMIA; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EARLY DIAGNOSIS; FEBRILE NEUTROPENIA; HUMAN; INFECTION; LEUKOPENIA; META ANALYSIS; METASTASIS; MODULATION; MORTALITY; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; PALLIATIVE THERAPY; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STOMACH CANCER; SURVIVAL TIME; SYSTEMIC THERAPY; TOXICITY; TREATMENT OUTCOME; VOMITING;

EID: 2642511340     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2004.04.014     Document Type: Article

References (35)

1. Earle C.C., Maroun J.A. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur. J. Cancer. 35(7):1999;1059-1064
2. Kohne C.H., Wils J.A., Wilke H.J. Developments in the treatment of gastric cancer in Europe. Oncology. 14(12 suppl 14):2000;22-25
3. Pyrhönen S., Kuitunen T., Nyanodoto P., Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br. J. Cancer. 71(3):1995;587-591
4. Murad A.M., Santiago F.F., Petroianu A., Rocha P.R., Rodrigues M.A., Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 72(3):1993;37-41
5. Scheithauer W, Kornek G, Zeh B, et al. Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer: A randomized trial (abstract). Second International Conference on Biology, Prevention and Treatment of GI Malignancies, 1995. Köln, 1995:68
6. Glimelius B., Ekstrom K., Hoffman K., et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol. 8:1997;163-168
7. Glimelius B., Hoftmann K., Haglund U., et al. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann. Oncol. 5:1994;189-190
8. Kelsen D., Atiq O.T., Saltz L., et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J. Clin. Oncol. 10(4):1992;515-516
9. Kim N.K., Park Y.S., Heo D.S., et al. A phase III randomised study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 71(3):1993;3818-3818
10. Ohtsu A., Shimada Y., Shirao K., et al. Randomised phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japanese Clinical Oncology Group Study (JCOG9205). J. Clin. Oncol. 21(3):2003;54-59
11. Vanhoefer U., Rougier P., Wilke H., et al. Final results of a randomised phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organisation for Research and Treatment of Gastrointestinal Tract Cancer Cooperative Group. J. Clin. Oncol. 18(14):2000;2648-2657
12. Waters J.S., Norman A., Cunningham D., et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br. J. Cancer. 80:1999;269-272
13. Cervantes A., Navarro M., Carrato A., et al. The addition of cisplatin to continuous infusion 5-fluorouracil for the treatment of advanced gastric cancer. Results of two consecutive phase II trials of the Spanish Group for Gastrointestinal Tumor Therapy (TTD). Proc. Am. Soc. Clin. Oncol. 18:1999;. (Abstract 980)
14. Cascinu S., Labianca R., Alessandroni P., et al. Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-deoxirubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J. Clin. Oncol. 15:1997;3313-3319
15. Hermans J., Bonenkamp J.J., Boon M.C., et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J. Clin. Oncol. 11:1993;1441-1447
16. Mari E., Floriani I., Tinazzi A., et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann. Oncol. 11:2000;837-843
17. Panzini I., Gianni L., Fattori P.P., et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomised trials and comparison with previous meta-analyses. Tumori. 88:2002;21-27
18. Hu J.K., Chen Z.X., Zhou Z.G., et al. Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials. World J. Gastroenterol. 8(3):2002;1023-1028
19. Neri B., Cini G., Andreoli F., et al. Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. Br. J. Cancer. 84(3):2001;875-877
20. Bajetta E., Buzzoni R., Mariani L., et al. Adjuvant chemotherapy in gastric cancer: 5 year results of a randomized study by the Italian Trials in Medical Oncology (ITMO) Group. Ann. Oncol. 13(3):2002;299-307
21. Nashimoto A., Nakajima T., Furukawa H., et al. Randomised trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J. Clin. Oncol. 21(3):2003;2234-2236
22. Di Constanzo F., Gasperoni S., Manzione L., et al. Post-operative chemotherapy (CT) in resected gastric cancer (GC): follow-up (FUP) vs pelf. Results of an Italian intergroup (GOIRC & GISCAD) study. Proc. Am. Soc. Clin. Oncol. 22:2003;296. (Abstract 1189)
23. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345(3):2001;725-730
24. Allum W., Cunningham D., Weeden S., et al. Perioperative chemotherapy in operable gastric cancer and lower oesophageal cancer: a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). Proc. Am. Soc. Clin. Oncol. 22:2003;. (Abstract 998)
25. Ajani J.A., Van Cutsem E., Moiseyenko S., et al. Docetaxel (D), cisplatin, 5-fluorouracil compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomised phase III trial (V325). Proc. Am. Soc. Clin. Oncol. 22:2003;249. (Abstract 999)
26. Louvet C., Andr ē T., Tigaud J.M., et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J. Clin. Oncol. 20(23):2002;4543-4548
27. Tebbutt N., Norman A., Cunningham D., et al. Randomised, multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophago-gastric cancer: interim analysis. Proc. Am. Soc. Clin. Oncol. 21:2002;. (Abstract 1031)
28. Gadgeel S.M., Shields A.F., Heilbrun L.K., et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am. J. Clin. Oncol. 26(3):2003;37-41
29. Pozzo C., Bugat R., Peschel C., et al. Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastric-oesophageal junction adenocarcinoma; final results of a randomized phase II study. Proc Am Soc Clin Oncol. 20:2001;. (Abstract 531)
30. Bouche O., Raoul J.L., Giovaninini M., et al. Randomized phase II trial of LV5FU2, LV5FU2-cisplatinum or LV5FU2-irinotecan in patients (pts) with metastatic gastric or cardial adenocarcinoma (MGA): final results of study FFCD 9803. Proc. Am. Soc. Clin. Oncol. 22:2003;. (Abstract 1033)
31. Schleucher N., Tewes M., Wilke H.J., et al. Phase I/II study with weekly infusional high-dose 5-fluorouracil/leucovorin/irinotecan in combination with biweekly cisplatin as first-line chemotherapy for metastatic gastric carcinoma. Proc. Am. Soc. Clin. Oncol. 22:2003;. (Abstract 1378)
32. Wils J. The treatment of advanced gastric cancer. Semin. Oncol. 23(3):1996;397-406
33. Massuti B., Cervantes A., Aranda E., et al. A phase II multicentric randomized trial in advanced gastric cancer (GC): fluorouracil. + leucovorin + epirubicin + cisplatin (FLEP) vs fluorouracil + adriamycin + methotrexate + leucovorin (FAMTX): response and survival report. Proceedings of the Sixth International Congress on Anti-cancer Treatment, Paris, France, February 6-9, 1996 Paris, Service d'Oncologie, Médical Hospital Pitié- Salpetrière. 120:1996;. (Abstract UI:97614417)
34. Roth A., Kolaric K., Zupanc D., Oresic V., Roth A., Ebling Z. High doses of 5-fluorouracil and epirubicin with or without cisplatin in advanced gastric cancer: a randomized study. Tumori. 85:1999;234-238
35. Cocconi G., Carlini P., Gamboni A., et al. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin, and methotrexate (FAMTX) in advanced gastric carcinoma. Ann. Oncol. 14:2003;1258-1263